Today, we’re looking at a new multiple myeloma approval for Bristol Myers Squibb, PBMs embracing TrumpRx price comparisons, and Novartis winning a key U.K. patent fight over Entresto.
My son built a structurally sound bridge yesterday out of latticed twigs; it supported my weight and also his. It was a moment of great pride. Hire him, he’s 8.
Bristol’s Zenbexus wins accelerated approval in multiple myeloma
The Food and Drug Administration yesterday approved an oral treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of medicine for the blood cancer and the first drug cleared by U.S. regulators using a more sensitive measure of remission.
Continue to STAT+ to read the full story…
